Von Willebrand factor (vWF) is a blood glycoprotein of the coagulation system. It is deficient or defective in von Willebrand disease and is involved in a large number of other diseases, including thrombotic thrombocytopenic purpura, Heyde's syndrome, and possibly hemolytic-uremic syndrome.
vWF is a large multimeric glycoprotein present in blood plasma and produced constitutively in endothelium? (in the Weibel-Palade bodies), megakaryocytes (α-granules of platelets), and subendothelial connective tissue.
VWF monomer and multimers
The basic vWF monomer is a 2050 amino acid protein. Every monomer contains a number of specific domains with a specific function; elements of note are:
- the D'/D3 domain, which binds to Factor VIII
- the A1 domain, which binds to:
- platelet gp1b-receptor
- possibly collagen
- the A3 domain, which binds to collagen
- the C1 domain, in which the RGD domain binds to platelet integrin αIIbβ3 when this is activated
- the "cysteine knot" domain (at the C-terminal end of the protein), which vWF shares with platelet-derived growth factor (PDGF), transforming growth factor-β (TGFβ) and β-human chorionic gonadotrophin (βHCG, of pregnancy test fame).
Monomers are subsequently [Glycans? N-glycosylated], arranged into dimers in the endoplasmic reticulum and into multimers in the Golgi apparatus by crosslinking of cysteine residues via disulfide bonds. With respect to the glycosylation?, vWF is one of the few proteins that carry blood group antigens (ABO system).
Multimers of vWF can be extremely large, >20,000 kDa, and consist of over 80 subunits of 250 kDa each. Only the large multimers are functional. Some cleavage products that result from vWF production are also secreted but probably serve no function.
Von Willebrand factor is not an enzyme and therefore has no catalytic activity. Its primary function is binding to other proteins, particularly Factor VIII and it is important in platelet adhesion to wound sites.
vWF binds to a number of cells and molecules. The most important ones are:
- Factor VIII is bound to vWF while inactive in circulation; Factor VIII degrades rapidly when not bound to vWF. Factor VIII is released from vWF by the action of thrombin.
- vWF binds to collagen, e.g., when it is exposed in endothelial cells due to damage occurring to the blood vessel.
- vWF binds to platelet gpIb when it forms a complex with gpIX and gpV; this binding occurs under all circumstances, but is most efficient under high shear stress (i.e., rapid blood flow in narrow blood vessels, see below).
- vWF binds to other platelet receptors when they are activated, e.g., by thrombin (i.e., when coagulation has been stimulated).
vWF appears to play a major role blood coagulation, and vWF deficiency or dysfunction (von Willebrand disease) therefore leads to a bleeding tendency, which is most apparent in tissues having high blood flow shear in narrow vessels. From studies it appears that vWF uncoils under these circumstances, decelerating passing platelets.
The biological breakdown (catabolism) of vWF is largely mediated by a protein cryptically termed ADAMTS13 (acronym of "a disintegrin-like and metalloprotease with thrombospondin type 1 motif no. 13"). It is a metalloproteinase which cleaves vWF between tyrosine at position 842 and methionine at position 843 (or 1605-1606 of the gene?). This breaks down the multimers into smaller units, which are degraded by other peptidases.
Role in disease
- Hereditary defects of vWF lead to von Willebrand disease (vWD), a bleeding diathesis of the skin and mucous membranes, causing nosebleeds, menorrhagia, and gastrointestinal bleeding. The point at which the mutation? occurs determines the severity of the bleeding diathesis.
- Some diseases affect the structure of vWF and lead to acquired vWD. Recently, Heyde's syndrome (bleeding from angiodysplasia in the colon in association with aortic valve stenosis) was shown to be due to breakdown of vWF high-molecular weight multimers.
- In thrombotic thrombocytopenic purpura (TTP), ADAMTS13 is either deficient or has been inhibited by antibodies directed at the enzyme. This leads to decreased breakdown of the ultra large multimers of vWF and microangiopathic hemolytic anemia with severe vascular symptoms.
vWF is named after Dr. Erik von Willebrand, a Finnish doctor who in 1924 first described a hereditary bleeding disorder in families from the Åland islands who had a tendency for cutaneous and mucosal bleeding, including menorrhagia. Although von Willebrand could not identify the definite cause, he distinguished von Willebrand disease (vWD) from haemophilia and other forms of bleeding diathesis.
In the 1950s, vWD was shown to be caused by a plasma factor deficiency (instead of being caused by platelet disorders), and, in the 1970s, the vWF protein was purified.